Kesimpta Presents A Mammoth Opportunity But Novartis Isn’t Seeing Rivals – Yet
Targeted B-Cell Therapy For Relapsing MS Projected To Achieve Peak Sales Of $6bn
Unlike the market-leading Ocrevus, biosimilar competition to Novartis’ Kesimpta blockbuster for multiple sclerosis hasn’t begun to materialize just yet, according to the Swiss originator.
